Who Do You Trust With Your Prostate: The Government or Your Doctor?

  • by: |
  • 05/22/2012
Another insipid, outdate and skewed report on cancer screening from the USPSTF.   How could AHRQ put this junk out, ignoring declining mortality rates from prostate cancer, particularly among the age groups that it claims should just be left to die?

"The challenge of ecologic data is that it is impossible to reliably separate out the relative effects of any changes in screening, diagnosis, or treatment practices (or fundamental changes in the underlying risk of developing or dying of the disease in the population due to a multiplicity of other causes) that may have been occurring simultaneously over a given time period. "

This is pure dissembling BS designed to justify rationing. 

Here is a more measured -- and patient-centered -- approach by urologist William Catalona:

The past half decade has seen a striking reduction of prostate cancer mortality rates in the US and other countries. The decrease has been ascribed, at least in part, to early diagnosis combined with more effective treatment, although there is no proof of a causal relationship.

Nevertheless, to the extent that early detection and effective treatment do reduce prostate cancer mortality and morbidity rates, PSA screening is clearly beneficial to many patients.

Some argue that PSA screening is not beneficial for all men screened because not every prostate cancer patient benefits from early diagnosis and treatment. Some tumors might never be life threatening and rare ones are incurable by the time the PSA level becomes elevated.

However, all available evidence suggests that PSA screening largely detects cancers that have features of clinically important cancers that are destined to cause suffering and death if untreated while they are still curable.

Some also argue that PSA screening is not beneficial to men who are never affected with prostate cancer. PSA screening does provide a feeling of well being in men who have persistently normal results, and even though a normal value can be misleading, with serial screening, PSA eventually reveals the cancer.

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog